These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 23500304)

  • 1. Pre-procedural estimate of individualized bleeding risk impacts physicians' utilization of bivalirudin during percutaneous coronary intervention.
    Rao SC; Chhatriwalla AK; Kennedy KF; Decker CJ; Gialde E; Spertus JA; Marso SP
    J Am Coll Cardiol; 2013 May; 61(18):1847-52. PubMed ID: 23500304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
    Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
    Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of a point-of-care bleeding risk calculator on anticoagulant selection in the coronary catheterization laboratory.
    Kerl JJ; Spexarth FC; Pedersen R; Stone M; Allaqaband SQ; Schulgit JL; Bajwa TK; Gupta AN; DeFranco AC
    Pharmacotherapy; 2015 Apr; 35(4):388-95. PubMed ID: 25884527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
    Sheikh-Taha M; Ghosn S
    J Pharm Pract; 2012 Oct; 25(5):537-40. PubMed ID: 22572222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of bleeding in renally impaired patients receiving incorrectly dosed eptifibatide or bivalirudin while undergoing percutaneous coronary intervention.
    Taylor LA; Mauro VF
    Ann Pharmacother; 2012 Jan; 46(1):35-41. PubMed ID: 22170973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.
    Shelton R; Eftychiou C; Somers K; Liu A; Burton-Wood N; Anderson M; Makri L; Blaxill J; McLenachan J; Wheatcroft S; Greenwood J; Blackman D
    EuroIntervention; 2013 May; 9(1):118-24. PubMed ID: 23410540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).
    Stone GW; Clayton T; Deliargyris EN; Prats J; Mehran R; Pocock SJ
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):15-20. PubMed ID: 24140664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.
    Cortese B; Micheli A; Picchi A; Bandinelli L; Brizi MG; Severi S; Limbruno U
    Coron Artery Dis; 2009 Aug; 20(5):348-53. PubMed ID: 19543084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body mass index and bleeding complications after percutaneous coronary intervention: does bivalirudin make a difference?
    Delhaye C; Wakabayashi K; Maluenda G; Belle L; Ben-Dor I; Gonzalez MA; Gaglia MA; Torguson R; Xue Z; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R
    Am Heart J; 2010 Jun; 159(6):1139-46. PubMed ID: 20569731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial).
    Parodi G; Migliorini A; Valenti R; Bellandi B; Signorini U; Moschi G; Buonamici P; Cerisano G; Antoniucci D
    Am J Cardiol; 2010 Apr; 105(8):1053-9. PubMed ID: 20381652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
    Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
    Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of bivalirudin hyper- and hypo-ACT responses in the setting of percutaneous coronary intervention.
    Weeks PA; Alkhateeb HM; Michaud SE; Diez JG
    J Invasive Cardiol; 2013 May; 25(5):250-3. PubMed ID: 23645051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
    JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Use and Impact of Bleeding Avoidance Strategies on Percutaneous Coronary Intervention-Related Bleeding Stratified by Predicted Risk.
    Gluckman TJ; Wang L; Spinelli KJ; Petersen JL; Huang P; Amin A; Messenger JC; Rao SV
    Circ Cardiovasc Interv; 2020 Jun; 13(6):e008702. PubMed ID: 32527190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalirudin therapy is associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database.
    Pinto DS; Ogbonnaya A; Sherman SA; Tung P; Normand SL
    Circ Cardiovasc Qual Outcomes; 2012 Jan; 5(1):52-61. PubMed ID: 22235065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of bivalirudin during percutaneous coronary interventions in patients with abnormal renal function.
    Roguin A; Steinberg BA; Watkins SP; Resar JR
    Int J Cardiovasc Intervent; 2005; 7(2):88-92. PubMed ID: 16093217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Rates Following Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry CathPCI Registry.
    Vora AN; Peterson ED; McCoy LA; Garratt KN; Kutcher MA; Marso SP; Roe MT; Messenger JC; Rao SV
    JACC Cardiovasc Interv; 2016 Apr; 9(8):771-779. PubMed ID: 27101904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Koutouzis M; Lagerqvist B; James S; Omerovic E; Matejka G; Grip L; Albertsson P
    Heart; 2011 Sep; 97(18):1484-8. PubMed ID: 21487123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
    Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN
    J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
    Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.